Geron Investors Ink $24M Deal Over Cancer Study Results
Geron Corp. investors have reached a $24 million settlement resolving their claims that the biotechnology company and its chief executive officer hid negative results of a clinical trial for a blood...To view the full article, register now.
Already a subscriber? Click here to view full article